DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA
BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS

a 2024

DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS

ČIMBOROVÁ, Katarína, Vendula PELKOVÁ, Tereza SOURALOVÁ, Naděžda VAŠKOVICOVÁ, Tomáš BÁRTA et. al.

Základní údaje

Originální název

DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS

Autoři

ČIMBOROVÁ, Katarína (703 Slovensko, domácí), Vendula PELKOVÁ (203 Česká republika, domácí), Tereza SOURALOVÁ (203 Česká republika, domácí), Naděžda VAŠKOVICOVÁ (203 Česká republika, domácí), Tomáš BÁRTA (203 Česká republika), Irena KOUTNÁ (203 Česká republika, domácí) a Aleš HAMPL (203 Česká republika, garant, domácí)

Vydání

SY-Stem 2024, Vienna, 2024

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10605 Developmental biology

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

macular degeneration; retina derivates; human pluripotent cells

Příznaky

Mezinárodní význam

Změněno: 21. 8. 2024 10:38, Mgr. Tereza Miškechová

Anotace

V originále

Regenerative medicine in the field of ophthalmology was revolutionized in the 1990s through stem cell-based therapies focusing on treating corneal diseases1. However, there still exist numerous incurable diseases associated with the perceptive part itself, the retina. The pathogenesis of the multiple forms of retinopathies is often associated with the dysfunction and loss of retinal cell types, including retinal pigment epithelium (RPE). Our objective is, thus, to establish for the first time in the Czech Republic the current Good Manufacturing Practise (cGMP) compliant methodological and regulatory grounds for producing a key component of the Advanced Therapy Medicinal Product – human pluripotent stem cell-derived RPE cells2. By doing so, we aim to contribute to the advancement of regenerative medicine, particularly in the treatment of retinal diseases. In our ongoing research, we have determined the optimal conditions for differentiation of hPSC into RPE cells, utilizing established protocols as a foundational reference. We have started with the establishment of the morphological, molecular, and functional criteria to assess the efficacy of the differentiation process, alongside a comprehensive evaluation of the genetic stability to ensure their safety. Our next steps involve the crucial transfer of this methodology to cGMP conditions, laying the groundwork for the translation of our findings into the realm of clinical applications.

Návaznosti

MUNI/A/1598/2023, interní kód MU

Název: Zdroje pro tkáňové inženýrství 14

Investor: Masarykova univerzita, Zdroje pro tkáňové inženýrství 14

NU22-08-00629, projekt VaV

Název: Vývoj postupů pro léčbu makulární degenerace sítnice deriváty lidských pluripotentních kmenových buněk

Investor: Ministerstvo zdravotnictví ČR, Vývoj postupů pro léčbu makulární degenerace sítnice deriváty lidských pluripotentních kmenových buněk, Podprogram 1 - standardní

Citovat

ČIMBOROVÁ, Katarína, Vendula PELKOVÁ, Tereza SOURALOVÁ, Naděžda VAŠKOVICOVÁ, Tomáš BÁRTA, Irena KOUTNÁ a Aleš HAMPL. DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS. In SY-Stem 2024, Vienna. 2024.

@proceedings{2415958,
   author = {Čimborová, Katarína and Pelková, Vendula and Souralová, Tereza and Vaškovicová, Naděžda and Bárta, Tomáš and Koutná, Irena and Hampl, Aleš},
   booktitle = {SY-Stem 2024, Vienna},
   keywords = {macular degeneration; retina derivates; human pluripotent cells},
   language = {eng},
   title = {DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS},
   year = {2024}
}

TY  - CONF
ID  - 2415958
AU  - Čimborová, Katarína - Pelková, Vendula - Souralová, Tereza - Vaškovicová, Naděžda - Bárta, Tomáš - Koutná, Irena - Hampl, Aleš
PY  - 2024
TI  - DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS
KW  - macular degeneration
KW  - retina derivates
KW  - human pluripotent cells
N2  - Regenerative medicine in the field of ophthalmology was revolutionized in the 1990s through stem cell-based therapies focusing on treating corneal diseases1. However, there still exist numerous incurable diseases associated with the perceptive part itself, the retina. The pathogenesis of the multiple forms of retinopathies is often associated with the dysfunction and loss of retinal cell types, including retinal pigment epithelium (RPE). Our objective is, thus, to establish for the first time in the Czech Republic the current Good Manufacturing Practise (cGMP) compliant methodological and regulatory grounds for producing a key component of the Advanced Therapy Medicinal Product – human pluripotent stem cell-derived RPE cells2. By doing so, we aim to contribute to the advancement of regenerative medicine, particularly in the treatment of retinal diseases. In our ongoing research, we have determined the optimal conditions for differentiation of hPSC into RPE cells, utilizing established protocols as a foundational reference. We have started with the establishment of the morphological, molecular, and functional criteria to assess the efficacy of the differentiation process, alongside a comprehensive evaluation of the genetic stability to ensure their safety. Our next steps involve the crucial transfer of this methodology to cGMP conditions, laying the groundwork for the translation of our findings into the realm of clinical applications.
ER  -

Podrobný výpis o publikaci